Statement of Principles concerning IgA nephropathy (Reasonable Hypothesis) (No. 63 of 2021)

The central legal concept in this instrument is the “reasonable hypothesis”, a standard derived from the VEA and MRCA that is lower than the balance of probabilities. The RMA determines that sound medical‑scientific evidence indicates that IgA nephropathy and death from it can be related to relevant service. The instrument then sets out the minimum factors that must exist before that hypothesis is accepted. “Clinical onset” refers to the first appearance or manifestation of IgA nephropathy; “clinical worsening” refers to a material deterioration that is not merely the natural progression of the disease. Distinguishing between onset and worsening is critical because factors 1-7 apply only to onset, while factors 8-18 apply only to worsening. A further condition for worsening factors is that the person’s IgA nephropathy must have been suffered or contracted before or during (but did not arise out of) the person’s relevant service. This temporal gateway means that for a worsening claim, the disease must pre‑exist the service or have occurred during service but from a non‑service cause. “Relevant service” is defined to include operational, peacekeeping, hazardous, and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA. The instrument uses a closed list for autoimmune diseases (ankylosing spondylitis, coeliac disease, inflammatory bowel disease, psoriasis, reactive arthritis, rheumatoid arthritis) and a closed list for infections (HIV, hydatid liver disease, hepatic portal schistosomiasis, Mycobacterium tuberculosis, Staphylococcus aureus). These lists are exhaustive and cannot be extended by analogy. The definition of “IgA nephropathy” itself is narrow: it requires a renal biopsy demonstrating IgA deposition in the renal mesangium plus clinical evidence of haematuria, proteinuria, or renal dysfunction. It excludes IgA vasculitis, which is a separate clinical entity. For death cases, the instrument extends coverage to death from a terminal event (such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function) that was contributed to by IgA nephropathy. The dictionary also defines “biologic agent” broadly as a therapeutic product derived from or containing living organisms, with non‑exhaustive examples including interferons, monoclonal antibodies, TNF‑α inhibitors, tyrosine kinase inhibitors, and VEGF antagonists. “Organic solvent” covers aliphatic, aromatic, chlorinated, and oxygenated hydrocarbon solvents. “Being overweight or obese” is defined solely by a BMI of 25 or greater, with BMI calculated as weight in kilograms divided by height in metres squared. “Pack‑year” is defined as 20 cigarettes per day for one year, or equivalent tobacco weight (7,300 grams). These definitions create clear, objective thresholds but may not capture clinical nuance. The concept of “inability to obtain appropriate clinical management” (factor 18) is left undefined, which introduces interpretive discretion. The instrument does not define what constitutes “appropriate clinical management” nor what constitutes “inability”, leaving that to the decision‑maker on the facts. This lack of definition could become a litigation risk.

The immediate legal effect is on veterans and members of the Australian Defence Force who have rendered relevant service and who suffer from IgA nephropathy or whose death is attributable to that disease. For a claim to be assessable under this instrument, the person must have operational, peacekeeping, hazardous, or British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA. Members of the Peacekeeping Forces under the VEA are also included. Persons with other types of service, such as peacetime service under the VEA (which is not defined as relevant service here), cannot rely on this SoP; they would need to rely on the general standard of proof under the VEA without a specific SoP, or on a different instrument. The instrument affects decision‑makers within the Department of Veterans’ Affairs, the Repatriation Commission, and the Military Rehabilitation and Compensation Commission, who must apply these factors when assessing liability and determining entitlements. It also affects the Administrative Appeals Tribunal and the Veterans’ Review Board, which review decisions. Treating nephrologists, pathologists, and general practitioners are indirectly affected because they must provide the clinical evidence that matches the definitions: a renal biopsy report confirming IgA deposition, documentation of haematuria or proteinuria, and evidence of the presence or absence of specified autoimmune diseases, infections, malignancies, liver disease, drug exposure, smoking history, weight history, and organic solvent exposure. The instrument also affects medical advisers who prepare reports and independent medical examiners. For the insurance and legal profession, the instrument creates a technical framework that must be understood to advise claimants or to challenge decisions. The broader veteran community with kidney disease may find their compensation prospects improved if they can satisfy a factor; conversely, those who cannot will find the threshold difficult to meet. The instrument also affects the RMA itself, which has ongoing obligations to review and update SoPs. The previous 2012 SoP is repealed, so any claims pending on 21 June 2021 rely on this instrument. There is a minor but real effect on the healthcare system: the requirement for biopsy means that not all cases of suspected IgA nephropathy will satisfy the definition, potentially forcing invasive diagnostic procedures for compensation purposes. Finally, the instrument affects taxpayers and government budgets, as successful claims under this SoP increase spending on disability pensions, medical treatment, and other benefits.

The instrument itself imposes no duties directly on individuals. The duties fall on the RMA to determine and publish SoPs, and on the Repatriation Commission and other decision‑makers to apply the SoP faithfully when making determinations under sections 120A of the VEA and 338 of the MRCA. The key right for a claimant is the right to have their claim assessed against the factors in section 9 Joseph and to have a reasonable hypothesis accepted if at least one factor exists and is related to service. Claimants also have the right to rely on the dictionary definitions: for example, they can rely on the specified lists of autoimmune diseases and infections being exhaustive, so that conditions outside those lists cannot be used against them as negative factors (the SoP does not include any negative factors). Claimants have the right to argue that a factor not listed in the SoP may still raise a reasonable hypothesis if it is otherwise supported by sound medical‑scientific evidence, but the SoP is designed to be the sole path. Under section 120A of the VEA, if an SoP covers a disease, the decision‑maker must apply it; they cannot depart from the factors. The right to judicial review of the SoP itself exists, as the instrument is a legislative determination, but that is a right under the broader law, not within this instrument. The instrument also gives claimants a right to rely on other SoPs through section 11, which provides that if a factor refers to an injury or disease covered by another SoP, the factors in that other SoP apply as in force from time to time. This cross‑reference means that a claimant with cirrhosis (factor 1) must also show that the cirrhosis itself is related to service under the relevant SoP for chronic liver disease. That creates a layered compliance burden. For decision‑makers, the duty is to assess each factor meticulously: they must be satisfied that the factor existed at the correct time (e.g., “at the time of the clinical onset” or “within the 30 days before” or “for at least the 7 days before”). They also must consider whether the factor is related to service under section 10(1). For worsening factors, they must check that the IgA nephropathy was not caused by service (section 10(2)). The instrument confers no discretion to ignore a factor that is met, but it also does not compel acceptance of a claim if the factor is not related to service. The duty to give reasons under the VEA applies separately, but the SoP itself does not address evidentiary standards. Claimants have a right to be informed of which factor is relied upon and how it is related to service. The instrument does not create a duty to seek out evidence; the burden of proof remains on the claimant, though the VEA’s reasonable hypothesis standard is relatively low.

This instrument contains no penalty provisions. It does not create an offence, and it does not impose fines, imprisonment, or civil penalties. Enforcement mechanisms for the underlying compensation system are located in the VEA and MRCA. For example, making a false or misleading statement in connection with a claim under the VEA may attract criminal penalties under the Criminal Code (Cth) or civil penalties under the VEA itself. Because the SoP is a legal instrument that decision‑makers must apply, failure to apply it correctly can be enforced through merits review (at the Veterans’ Review Board and the Administrative Appeals Tribunal) and judicial review in the Federal Court or the High Court. A decision‑maker who disregards the SoP may have their decision set aside. There is no direct penalty for the RMA if the SoP is later found to be unreasonable, as the RMA has broad discretion under section 196B. The instrument does not create a private right of action against the Commonwealth. The practical enforcement of the SoP is through the claims process: if a claim is rejected because a factor was not recognised, the claimant can challenge that decision prospectively. The instrument does not require decision‑makers to audit or police compliance beyond their own assessment. For claimants, the risk of making a claim that relies on a factor that is not supported by evidence is simply that the claim fails, not that a penalty is imposed. However, if a claimant knowingly fabricates evidence of a factor, the general law on fraud applies. The SoP itself does not address evidentiary standards such as on‑us of proof beyond “reasonable hypothesis”. The VEA provides that the Commission is to determine the claim to its reasonable satisfaction; this SoP is a device to structure that satisfaction. The absence of penalties within the instrument means that it is purely an evidentiary rule, not a regulatory code.

The instrument operates within the statutory framework of the VEA and the MRCA. Section 3 states that it is made under subsection 196B(2) of the VEA, and section 5 confirms it applies to claims under section 120A of the VEA or section 338 of the MRCA. These provisions require that a Statement of Principles be considered in determining whether a disease is war‑caused or defence‑caused. The instrument repeals the earlier SoP No. 52 of 2012, so from 21 June 2021, all pending and new claims for IgA nephropathy fall under this instrument. The instrument interacts with other SoPs through section 11: where a factor in this SoP refers to an injury or disease covered by another SoP, the factors in that other SoP apply. For example, factor 2 requires an autoimmune disease from the specified list. If a veteran has rheumatoid arthritis, the decision‑maker must also consider whether that rheumatoid arthritis is related to service under the relevant SoP for rheumatoid arthritis (if one exists). That creates a cascade: the claimant must satisfy not only this SoP but also the other SoP to establish the factor’s relation to service. Similarly, factor 4 requires an infection from the specified list, and the infection itself may have its own SoP if it is a disease covered by another SoP. This interaction can significantly increase the compliance burden for claimants with multiple conditions. The instrument also interacts with the general law of causation as developed in cases under the VEA, such as the requirement that the factor must be related to service in a way that is not too remote. However, no cases are named in this source. The instrument does not interact with state workers’ compensation schemes, the National Disability Insurance Scheme, or private health insurance, except indirectly because a veteran may seek compensation under multiple regimes and the existence of a VEA determination may affect other assessments. The instrument also interacts with the criminal law only to the extent that fraud is an offence generally. It does not interact with the Therapeutic Goods Act or the Poisons Standard, though the definition of “biologic agent” draws on concepts from therapeutic regulation. The instrument’s definitions of “organic solvent” and “being overweight or obese” are sui generis; they do not necessarily match definitions used in workplace health and safety law or the National Health and Medical Research Council guidelines boots. This can create confusion where a claimant’s medical records use a different definition of obesity (e.g., BMI 30) or a different classification of solvents.

The instrument records only one amendment event: it repeals the Statement of Principles concerning mesangial IgA glomerulonephritis No. 52 of 2012 (F2012L01792). That 2012 SoP was made under the same subsection of the VEA and applied to the same disease. The current instrument does not list any amendments prior to its making; it is a fresh determination. The commencement date is 21 June 2021, and the instrument is dated 21 May 2021. There is no indication of any subsequent amendments up to the date of this source. As a legislative instrument, it may have been amended after the version provided, but those amendments are not reflected here. The repeal of the 2012 SoP is the only history given. The instrument does not refer to any transitional provisions, so claims that were lodged but not finally determined before 21 June 2021 would be assessed under the new SoP, unless the old SoP was more beneficial and a transitional clause elsewhere provides otherwise (none is evident). The instrument does not state its purpose by reference to any review or updated medical evidence, though the RMA is presumed to act on sound medical‑scientific evidence. The shift from the 2012 SoP may have involved changes to the factor list, but the source provides no details of what was in the 2012 SoP. The instrument’s amendment history is minimal, which is typical for SoPs that replace earlier versions tout court.

This source does not name any litigation involving this specific instrument. Statements of Principles under the VEA are subject to judicial review, and challenges have been brought in the Federal Court and the High Court regarding the validity of particular factors or the reasonableness of the RMA’s determination. However, because this instrument is from 2021 and the source is provided without updates, no decisions are cited. The previous 2012 SoP may have been the subject of litigation, but that is not recorded here. Given the technical nature of the definitions, potential litigation points include: whether the definition of “IgA nephropathy” requires a biopsy even where biopsy is contraindicated; whether the specified lists of autoimmune diseases and infections are arbitrary; whether the “clinical worsening” factors adequately account for the natural history of the disease; and whether the requirement that the factor be related to service is too demanding. The instrument’s silence on the meaning of “inability to obtain appropriate clinical management” (factor 18) is fertile ground for dispute. There may also be litigation about the meaning of “taking a drug which is associated in the individual” - whether that requires a documented positive rechallenge or whether a strong temporal association suffices. The instrument does not define “associated in the individual”, leaving it to clinical judgment. Another potential challenge is to the requirement that biologic agents be taken for at least seven days before clinical onset or worsening: does that capture intermittent dosing regimens? The instrument does not address long‑acting biologics. The lack of litigation history in the source means the instrument is relatively untested. Practitioners should monitor the Federal Court for appeals from the Administrative Appeals Tribunal on these points.

The instrument has several traps that can easily mislead a reader. First, the definition of “IgA nephropathy” requires a renal biopsy demonstrating IgA deposition in the renal mesangium. A clinical diagnosis without biopsy is insufficient for the SoP, even if the condition is clinically obvious. A claimant who refuses biopsy, or for whom biopsy is contraindicated, cannot satisfy the definition and therefore cannot succeed under this SoP. Second, the exclusion of IgA vasculitis is absolute; a person with Henoch‑Schönlein purpura with renal involvement is not covered, even if the clinical and pathological features are nearly identical. Third, the worsening factors (8-18) only apply where the IgA nephropathy was suffered or contracted before or during (but did not arise out of) the person’s relevant service. That means if the disease first became manifest during service and was caused by service, the worsening factors cannot be used - only onset factors apply. This creates a perverse outcome where a service‑caused IgA nephropathy may not be compensable for later worsening if no ongoing factor exists. Fourth, factor 18 (“inability to obtain appropriate clinical management”) is undefined and may be interpreted narrowly. It does not cover mere delay in diagnosis or suboptimal treatment; the claimant must prove they were actually unable to obtain appropriate clinical management, not just that management was less than ideal. Fifth, the organic solvent exposure factor (17) is highly specific: it must be in an unventilated and confined space for an average of at least two hours per week for at least one year within the five years before clinical worsening. Casual or occupational exposure in ventilated areas does not count. This is a high bar that few claimants will meet. Sixth, the smoking factor (16) requires at least five pack‑years in the ten years before clinical worsening wag. A person who smoked heavily but quit more than ten years before worsening cannot rely on it. Seventh, the weight factor (15) requires being overweight or obese (BMI ≥25) for at least five years before worsening. Intermittent obesity or recent weight gain may not suffice. Eighth, the drug factors (5 and 12) require either improvement within three months of discontinuing or tapering, or redevelopment on rechallenge. This imposes an evidential burden of a therapeutic trial that may never have been performed. If a drug is stopped but the nephropathy does not improve within three months, factor 5(a) is not met. If the drug is never restarted, factor 5(b) is not met. This creates a catch‑22 if the drug’s association is known from literature but not clinically demonstrated in the individual. Ninth, the “specified list of autoimmune diseases” is exhaustive and does not include common autoimmune conditions such as systemic lupus erythematosus or Sjögren’s syndrome. A claimant with lupus and IgA nephropathy cannot use factor 2. Tenth, the “specified list of infections” includes only five infections; common infections like hepatitis B, hepatitis C, or cytomegalovirus are not there. Eleventh, the cross‑reference in section 11 means that proving a factor often requires satisfying a whole other SoP, increasing the evidentiary burden. Finally, the instrument does not define “clinical onset” or “clinical worsening” with a timeframe, leaving room for argument about when the disease first manifested or materially worsened.

Compliance with this instrument is primarily the responsibility of decision‑makers assessing claims, but claimants and their advisers must also understand how to structure evidence. For a successful claim, the first step is to confirm that the person has relevant service as defined. Then obtain a renal biopsy report that unequivocally shows IgA deposition in the renal mesangium, and clinical evidence of haematuria, proteinuria, or renal dysfunction. The biopsy must be contemporaneous with the clinical findings. Exclude IgA vasculitis. Next, determine whether the claim is for clinical onset or for clinical worsening. For onset, review factors 1-7. Gather evidence: if the claimant has cirrhosis or chronic liver disease, obtain a hepatologist’s report confirming progressive liver destruction and abnormal function for at least six months (see definition). For autoimmune disease, check the specified list: ankylosing spondylitis, coeliac disease, inflammatory bowel disease, psoriasis, reactive arthritis, or rheumatoid arthritis. A rheumatologist or gastroenterologist report confirming the diagnosis at the time of onset is needed. For malignant neoplasm, any cancer is sufficient; no list is given. For infection, confirm one of the five specified infections and document that it occurred within the 30 days before clinical onset. For drug‑induced cases, obtain a clear history of the drug being taken for at least seven days before onset, and ideally evidence of improvement upon cessation or recurrence on rechallenge. The claimant should have medical records documenting the temporal relationship. For biologic agents, confirm the agent was for cancer or autoimmune disease and taken for at least seven days before onset. For kidney transplantation, document the date of transplant relative to onset. For worsening claims (factors 8-18), the most important trap is that the IgA nephropathy must have been present before or during service but not caused by service. That means the claim will fail if service caused the initial disease. For worsening, also gather evidence of cirrhosis, liver disease, autoimmune disease, malignancy, infection, drug exposure, or biologic agent as for onset, but directed at the time of worsening. For organic solvent exposure, obtain a detailed occupational or environmental history: the exposure must be in an unventilated and confined space, average at least two hours per week for at least one year within five years before worsening. For smoking, verify the pack‑year calculation using the formula: (cigarettes per day / 20) × years smoked, and ensure the total is at least five pack‑years and that the smoking occurred within ten years before worsening. For obesity, calculate BMI and confirm it was 25 or greater for at least five continuous years before worsening. For inability to obtain appropriate clinical management, gather evidence of specific barriers such as lack of access to a nephrologist, inability to afford medications, or denial of treatment by a health service. This factor is the most subjective and will rely on the decision‑maker’s judgment. Finally, for every factor, the claimant must demonstrate that the factor itself is related to relevant service under section 10(1). That means the cirrhosis, infection, smoking, obesity, or solvent exposure must have been caused by or associated with service. This is often the hardest element. Advisers should prepare a nexus statement linking the factor to an event, condition, or exposure during service. Where the factor is itself a disease covered by another SoP, the claimant must satisfy that other SoP as well. Compliance requires meticulous documentation and a deep understanding of the definitions in Schedule 1. The easiest path is often factor 18 (inability to obtain clinical management) if the veteran can show that service‑related factors prevented proper care, but that is also the most uncertain.